Luminex’s well-timed plans to acquire Tm Bioscience may end up transforming the company into a formidable player in pharmacogenomics. 
 
Luminex’s announcement last week that it plans to acquire Tm Bioscience in a stock-for-stock deal worth roughly $44 million comes months after Tm said it aimed to submit several assays for regulatory clearance in the US, including three P450 mutation detection kits and a warfarin CYP2C9 and VKORC1 mutation detection kit.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.